4SC Announces Capital Increase

(PresseBox) ( Planegg-Martinsried, )
4SC AG (Frankfurt, Prime Standard: VSC) the drug discovery and development company, today announced that its Management Board, with the approval of the Supervisory Board, decided to increase the Company's share capital from EUR 28,502,739.00 up to EUR 39,903,834.00 through the issue of up to 11,401,095 common ordinary bearer shares at zero par value from the authorised capital. The new shares will be offered at a subscription price of EUR 3.00 per new share to the shareholders.

The Company intends to raise in the range of EUR 25 to 30 million. The proceeds will secure the further development of 4SC's current product pipeline. In particular, the focus will be on the further development of clinical and preclinical compounds against auto-immune and cancer indications, for which proof-of-concept is expected to be achieved within the next 24 months.

The subscription rights of the shareholders have been protected. The new shares with dividend rights from 1 January, 2009, can be obtained by shareholders in a ratio of 5:2 from 27 October until 10 November 2009. In the following any unsubscribed shares will be offered to new institutional investors. A public offer for the purchase of the new share capital will not occur. The approval of the new shares for trading at the Frankfurt Stock Exchange is not expected before November/December 2009. Further details of the capital increase will be published in the electronic Federal Register (Bundesanzeiger), which is expected on the 27 October, 2009.
The publisher indicated in each case is solely responsible for the press releases above, the event or job offer displayed, and the image and sound material used (see company info when clicking on image/message title or company info right column). As a rule, the publisher is also the author of the press releases and the attached image, sound and information material.
The use of information published here for personal information and editorial processing is generally free of charge. Please clarify any copyright issues with the stated publisher before further use. In the event of publication, please send a specimen copy to service@pressebox.de.